ToxicoGenomica recently presented at the National Asbestos Litigation Conference (September 12-13, 2023) hosted by Perrin Conferences and the slides are now available for download. Len van Zyl, Ph.D, and CEO of ArrayXpress participated in an engaging panel moderated by Douglas Sinars, Esq. and titled Medical & Scientific Literature Update on Asbestos & Mesothelioma. The panel […]
ToxicoGenomica recently presented a webinar organized by Perrin Conferences and the slides are now available for download. The webinar focused on the latest publications, scientific studies, and statistics regarding genomics role in cancers. It also covered predictive software and other tools for understanding the impact of germline mutations on disease development and progression. The speakers […]
Join us for this complimentary CLE webinar on Tuesday, July 18, 2023 from 2:00-3:30 pm ET. This webinar will focus on the latest publications, scientific studies, and statistics regarding genomics role in cancers. It will also cover predictive software and other tools for understanding the impact of germline mutations on disease development and progression. There […]
Kirk Hartley of ToxicoGenomica will cover the topic of the continually increasing value of genomic analysis to evaluate mesothelioma causation at the upcoming Perrin Conference on Cutting-Edge Issues in Asbestos Litigation. As part of a panel on genetics and science, Kirk will discuss important new papers with data showing the increasing findings of genomic drivers of mesotheliomas. One portion […]
ToxicoGenomica recently presented a webinar organized by Perrin Conferences and the slides are now available for download. The title of the session was Key Developments: Genomics in Mesothelioma Cases. The webinar focused on the latest cases, the most recent science and publications, and the evolving applications and cost of deployment of the science of genomics […]
Complimentary CLE Webinar Thursday, December 1st, 2022 1:30-2:45 ET Click Here For More Information and to Register This webinar will focus on the latest cases, the most recent science and publications, and the evolving applications and cost of deployment of the science of genomics to understanding the causes of cancer. MEET THE SPEAKERS • Kirk […]
Identifying protective mutations through comprehensive genetic screening gives litigators more leverage to argue disease causation in court. Protective mutations are certain altered points in an individual’s DNA that can give them robust resistance to developing disease even if exposed to a known causative agent. Accordingly, if genetic testing shows that a particular person harbors resistance […]
Stakeholders involved in toxic tort litigation involving Amyotrophic Lateral Sclerosis (ALS) will want to understand the implications of a recent study that identified previously unknown genetic factors involved in the development of this disease. The authors explained that the results are notable for multiple reasons, including “reveal[ing] genetic variants that protect against ALS by reducing […]
Legal defenses in toxic tort cases regarding mesothelioma or lymphoma are increasingly dependent on genetic evidence demonstrating genetic predisposition – i.e., demonstrating that the cancer was caused by genetic defects that the plaintiff inherited. In the case of other cancers, however, litigators may face a lack of data supporting legal arguments of predisposition. For litigators […]
Two decades after the initial draft from the Human Genome Project, the very first seamless and gap-free sequence of the entire human genome has been completed by the Telomere to Telomere (T2T) consortium. Researchers involved in the breakthrough call this advancement “[critical] for understanding the genetic contributions to certain diseases”. In toxic tort, this advancement […]